AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3907288
Drug: Toluene exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toluene exposure (382 mg/m3 for 6 1/2 hours)
Trial: 29146657
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy, diet and exercise for 12 months
Trial: 17156651
Drug: niacin ER
RxNorm normalized name: Niacin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER 500 mg/d for 4 weeks and then 1000 mg/d for 4 weeks
Trial: 17156651
Drug: atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 mg/d for 8 weeks
Trial: 17156651
Drug: atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin (10 mg/d) plus niacin ER (starting from 500 mg/d to 1000 mg/d after 4 weeks) for 8 weeks
Trial: 1401694
Drug: Nandrolone 2
RxNorm normalized name: nandrolone 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nandrolone 2 mg/kg
Trial: 3908352
Drug: Naltrexone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (200 mg daily)
Trial: 27242010
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene with sterile water (SG)
Trial: 29900909
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy (scaling and root planning)
Trial: 21259024
Drug: CHO-PRO (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO (18 g L(‐1) PRO, 72 g L(‐1) CHO)
Trial: 21259024
Drug: PLA (76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (76 g L(‐1) CHO)
Trial: 19038426
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy‐Prostate scores
Trial: 11589384
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of physiological dose of PYY
Trial: 7651811
Drug: Uppercase consonant
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uppercase consonant trigrams (e.g., FMH) as primes
Trial: 320951
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) and FT‐207 at the same dose schedule
Trial: 21268722
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rt-PA) (1 mg in each lumen) once weekly
Trial: 21268722
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 U per milliliter) three times per week
Trial: 17509249
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment for MS symptoms
Trial: 17509249
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for MS symptoms
Trial: 9277416
Drug: Low-dose atropine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atropine (5 micrograms.kg‐.h‐1)
Trial: 9277416
Drug: CCK‐A receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK‐A receptor antagonist loxiglumide (22 mumol.kg‐.h‐1)
Trial: 19049556
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CoQ(10)/vitamin E therapy
Trial: 19049556
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose CoQ(10)/vitamin E therapy
Trial: 11083192
Drug: Adenosine-exercise (treadmill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine-exercise (treadmill exercise during adenosine infusion)
Trial: 11083192
Drug: Adenosine-nonexercise (adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine-nonexercise (adenosine infusion alone)
Trial: 9193193
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of d,l-fenfluramine hydrochloride (Pondimin)
Trial: 8064072
Drug: Nedocromil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil (4 mg)
Trial: 8626987
Drug: Furosemide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (30 mg)
Trial: 8064072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nedocromil and furosemide
Trial: 433806
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g nitrogen diet
Trial: 1163469
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g nitrogen diet
Trial: 1163469
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement of 0.9 g on the 12 g nitrogen diet
Trial: 1163469
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g nitrogen diet
Trial: 21327728
Drug: Transtympanic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transtympanic steroid injections (Group A)
Trial: 21327728
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of steroids (Group B)
Trial: 16489524
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (very-point technique)
Trial: 15355582
Drug: Psychodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic therapy
Trial: 10647539
Drug: DRINK (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRINK (oral rehydration, 0.45% NaCl)
Trial: 10647539
Drug: IV (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (intravenous rehydration, 0.45% NaCl)
Trial: 7537488
Drug: Alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 2.5 mg tid
Trial: 7537488
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens 160 mg bid
Trial: 1963273
Drug: Pirarubicin (THP)
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) at 55 mg/m2, Etoposide at 100 mg/m2 (days 1-3), Vincristine at 2 mg (day 1)
Trial: 1963273
Drug: Pirarubicin (THP)
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) at 60 mg/m2
Trial: 1963273
Drug: Pirarubicin (THP)
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) at 40 mg/m2, 50 mg/m2, and 55 mg/m2
Trial: 1963273
Drug: Pirarubicin (THP)
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (THP) at 55 mg/m2
Trial: 14686965
Drug: Acarbose, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose, 150 mg/day
Trial: 11829107
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) at a daily dose of 60 mg
Trial: 776487
Drug: Atenolol 75
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 75 mg/day, increased to a maximum of 900 mg if tolerated
Trial: 776487
Drug: Atenolol therapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol therapy after 8 weeks
Trial: 28643825
Drug: Implant-supported removable
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported removable partial denture with implants placed in the molar region
Trial: 28643825
Drug: Implant-supported removable
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported removable partial denture with implants placed in the pre-molar region
Trial: 21574446
Drug: Cytoflavin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin as a component of combined therapy
Trial: 16952987
Drug: Anti-TNF-alpha therapy
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-alpha therapy
Trial: 11275039
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (3 million IU daily for 5 days, followed by 2 days of rest for 3 weeks)
Trial: 8292640
Drug: Experimental condition:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental condition: one monthly non‐random urine screen, one monthly counseling session, one monthly doctor visit, two times per month methadone pick up, a quarterly true random urine screen and participation in a diversion control program
Trial: 2949920
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin (0.30 U/kg)
Trial: 2949920
Drug: Porcine ultralente
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine ultralente insulin (0.30 U/kg)
Trial: 2949920
Drug: Bovine ultralente
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine ultralente insulin (0.30 U/kg)
Trial: 26362831
Drug: Valsartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (angiotensin receptor blocker)
Trial: 12904684
Drug: Amlodipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (calcium channel blocker)
Trial: 17559152
Drug: PEGIFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day + EPO 40,000 U/week
Trial: 17559152
Drug: PEGIFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGIFN alpha‐2b + WBR 13.3 mg/kg/day
Trial: 17559152
Drug: PEGIFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGIFN alpha‐2b + higher dose WBR 15.2 mg/kg/day + EPO
Trial: 28939589
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who had never used hormone therapy
Trial: 25386711
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron treatment (500 mg)
Trial: 20844049
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) therapy
Trial: 11784431
Drug: Sulfadoxine-pyrimethamine (Fansidar)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (Fansidar) as replacement therapy
Trial: 56146
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (HES) 500 ml during surgery and on the following three days
Trial: 56146
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution 500 ml during surgery and on the following three days
Trial: 3276390
Drug: Chemotherapy arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy arms
Trial: 18569274
Drug: Silica gel
RxNorm normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silica gel
Trial: 28291842
Drug: Opioid remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid remifentanil (0.15 μg/kg/min) administered intravenously for 60 minutes
Trial: 15126714
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g x kg NaHCO3
Trial: 15126714
Drug: 0.207 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.207 g x kg NaCl (CON)
Trial: 8160720
Drug: Psyllium fiber
RxNorm normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium fiber (6.7 g daily)
Trial: 29948956
Drug: Pyridoxine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (60 mg per day)
Trial: 18471512
Drug: Terlipressin (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1-2 mg/4 hour, intravenously) and albumin (1 g/kg followed by 20-40 g/day)
Trial: 12921475
Drug: SLI381 (Adderall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 (Adderall XR) 10 mg
Trial: 12921475
Drug: SLI381 (Adderall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 (Adderall XR) 20 mg
Trial: 12921475
Drug: SLI381 (Adderall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI381 (Adderall XR) 30 mg
Trial: 12921475
Drug: Adderall 10
RxNorm normalized name: Adderall 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall 10 mg (active control)
Trial: 9044877
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg and 160 mg)
Trial: 3899554
Drug: Postprandial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial exercise preceded by the usual dose of insulin
Trial: 3899554
Drug: Postprandial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial exercise preceded by one-half of the usual dose of insulin
Trial: 3899554
Drug: Postprandial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial exercise preceded by two-thirds of the usual dose of insulin
Trial: 3899554
Drug: Postprandial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial exercise without the usual dose of insulin
Trial: 2929911
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg
Trial: 12196659
Drug: Oral albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral albuterol for 6 months
Trial: 10503860
Drug: GM-CSF mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF mouthrinse (0.5 microg/mL), administered for 1 minute 3 times per day after oral hygiene procedures, starting from the first day of mucositis until clinical improvement.
Trial: 10503860
Drug: GM-CSF mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF mouthrinse (0.5 microg/mL).
Trial: 1914267
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of sublingual nitroglycerin without transdermal nitroglycerin (Group 1)
Trial: 1914267
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of sublingual nitroglycerin with 12-hour-daily intermittent therapy of transdermal nitroglycerin (Group 2)
Trial: 1914267
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 3)
Trial: 1914267
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 4)
Trial: 31524642
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (neoadjuvant)
Trial: 31524642
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TRG and TNM
Trial: 24980290
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVOO, 10 g)
Trial: 24980290
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (10 g)
Trial: 2110386
Drug: Ifosfamide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (8 to 10 g/m2) with mesna uroprotection, bolus administration
Trial: 2110386
Drug: Ifosfamide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (8 to 18 g/m2) with mesna uroprotection, continuous infusion
Trial: 2110386
Drug: Ifosfamide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (up to 18 g/m2)
Trial: 2110386
Drug: Ifosfamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (16 g/m2)
Trial: 2110386
Drug: Ifosfamide (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (18 g/m2)
Trial: 347992
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate intranasal aerosol
Trial: 31179799
Drug: Standard infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard infusion puncture method (Control)
Trial: 28591198
Drug: Single 45mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 45mg dose of primaquine (equivalent to three SLD PQ)
Trial: 28591198
Drug: Single 45mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 45mg dose of primaquine
Trial: 26202995
Drug: Probiotic lactobacilli
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lactobacilli (1 lozenge containing Lactobacillus reuteri DSM 17938 and ATCC PTA 5289, twice daily for 12 weeks)
Trial: 26202995
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 12 weeks)
Trial: 19388893
Drug: Midazolam (0.05-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.05-0.1 mg/kg orally)
Trial: 16455894
Drug: alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha interferon 2b (IFN-alpha2b) (3 million units three times a week) + ribavirin (800 mg/day)
Trial: 16455894
Drug: pegylated IFN-alpha2b
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated IFN-alpha2b (1.5 mug/kg of body weight/week) + ribavirin (800 mg/day)
Trial: 16455894
Drug: HCV CA
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV CA below the threshold value (4.18 log(10) pg/ml . 10(4))
Trial: 8607321
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg.kg‐1)
Trial: 30448246
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone (TAC) injections
Trial: 27906839
Drug: Bosentan (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (500 mg)
Trial: 26041745
Drug: AC→XT (Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC→XT (Capecitabine 825 mg/m² twice daily, days 1‐14; Docetaxel 75 mg/m² on day 1)
Trial: 26041745
Drug: AC→T (Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC→T (Doxorubicin and Cyclophosphamide followed by Docetaxel, T dose: 100 mg/m² on day 1)
Trial: 23377341
Drug: Ketoconazole foam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole foam, 2%, twice daily
Trial: 16113459
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (duration: 8 weeks)
Trial: 16113459
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (duration: 4 years)
Trial: 16113459
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (population: adults with asthma)
Trial: 11497388
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NK1 receptor antagonists with existing agents
Trial: 29324705
Drug: Chitosan treatment
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan treatment (3200 mg daily)
Trial: 17377389
Drug: 0.1% retinaldehyde/6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% retinaldehyde/6% glycolic acid cream (RALGA)
Trial: 17935515
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (control)
Trial: 9507234
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g highly purified ethyl esters of eicosapentaenoic acid (EPA) (95% pure)
Trial: 9507234
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g docosahexaenoic acid (DHA) (90% pure)
Trial: 1254157
Drug: Post-operative prophylactic
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative prophylactic chemotherapy
Trial: 1254157
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy for at least 2 years